Scleroderma Patients with Combined Pulmonary Hypertension and Interstitial Lung Disease

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2398-2405

  Chang, Betty ^a   Wigley, Fredrick M ^b   White, Barbara ^b   Wise, Robert A ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Interstitial lung disease; Pulmonary hypertension; Scleroderma

Indexed keywords

AUTOANTIBODY; DNA TOPOISOMERASE; DNA TOPOISOMERASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; LUNG VENTILATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESTRICTIVE VENTILATORY DEFECT; SCLERODERMA; SKIN DISEASE;

ADULT; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RESPIRATION DISORDERS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 0242524378     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995;22:2100-2.
2. Diot E, Buissinot E, Asquier E, et al. Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest 1998;114:1623-9.
3. Kim EA, Johkoh T, Lee KS, et al. Interstitial pneumonia in progressive systemic sclerosis: serial high resolution CT findings with functional correlation. J Comput Assist Tomogr 2001;25:757-63.
4. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
5. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2001;132:947-54.
6. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985;28:759-67.
7. Sacker MA, Heinz ER, Steinberg AJ. The heart in scleroderma. Am J Cardiol 1996;17:542-59.
8. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981;123:185-9.
9. Crapo RO. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
10. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Clin Respir Physiol 1982;18:419-25.
11. American Medical Association. Guides to the evaluation of permanent impairment. 4th ed. Chicago: American Medical Association; 1993.
12. Steen VD, Powell DL, Medsger TA. Clinical correlation and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
13. Rossa AD, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Bis 2001;60:585-91.
14. Owens GR, Fino GJ, Herbert DL, et al. Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983;84:546-50.
15. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
16. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
17. Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley FM. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine 1984;63:221-31.
18. Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
19. Medsger TA, Steen VD. Classification, prognosis. In: Clements PH, Furst DE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996:57-64.
20. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, du Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
21. Liang TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
22. Homma A, Anzueto A, Peters JI, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant 2001;20:833-9.
23. Papiris SA, Vlachoyiannopoulos PF, Maniati MA, Karakostas KX, Constantopoulos SH, Moutsopoulos HH. Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: two fibroses with different prognoses. Respiration 1997;64:81-5.
24. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respirol Crit Care Med 1998;157:1301-15.
25. Strange C, Bolster M, Mazur J, Taylor M, Gossage JR, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000;118:1077-82.